About: Everolimus in patients with multiply relapsed or cisplatin refractory germ cell tumors: results of a phase II, single-arm, open-label multicenter trial (RADIT) of the German Testicular Cancer Study Group

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Everolimus in patients with multiply relapsed or cisplatin refractory germ cell tumors: results of a phase II, single-arm, open-label multicenter trial (RADIT) of the German Testicular Cancer Study Group Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

article

Attributes	Values
rdf:type	Item
description	article (en) wetenschappelijk artikel (nl) наукова стаття, опублікована у вересні 2018 (uk) article scientifique publié en 2018 (fr) im September 2018 veröffentlichter wissenschaftlicher Artikel (de)
publication date	wds:Q57837577-855F3965-0D18-42A0-B849-D52FAF4C3EAA
publication date	2018-09-19 00:00:00Z (xsd:dateTime)
exact match	wds:Q57837577-BD7C38AD-5A97-430E-BD9F-3C6F04D3AD07
exact match	https://scigraph.springernature.com/pub.10.1007/s00432-018-2752-z
cites work	wds:Q57837577-023B3E1D-35AF-4C08-B60C-C9FC25CDDF4A wds:Q57837577-124594C8-0CD2-4AF7-8594-2377F388F1AB wds:Q57837577-30DE0F6E-7E90-46C3-9B4F-7B7E64921B04 wds:Q57837577-61B02FDB-E516-47E2-AD40-244EE00CEA29 wds:Q57837577-756A81E1-23E0-4533-BCC8-38426E1A2B17 wds:Q57837577-83CB27EC-8CD0-445A-A057-C5E9A3CEC5C8 wds:Q57837577-897B5DEA-DCD1-4C13-9FF5-03BE93CFAD37 wds:Q57837577-927097EA-F94E-425B-B8AB-9CB4DED41454 wds:Q57837577-9F4BCAE9-816F-44C4-BDF4-51437DCADD6E wds:Q57837577-A4A424B6-F318-4A3E-8EF3-49C4021680DB wds:Q57837577-AEA634FB-3917-4F22-9CFF-2553023E8321 wds:Q57837577-E34433EE-659D-4582-A4F2-1EAB58AFFECD wds:Q57837577-EDB5EA01-1FC1-4C35-9E99-CE72A706D2DE wds:Q57837577-EF26A201-683D-4E24-96EB-4769778E3D24 wds:Q57837577-FC003331-77EC-4CC7-992C-BE76C30D00C7
cites work	The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy Phase II study of everolimus in refractory testicular germ cell tumors. Phase II trial of sunitinib in patients with relapsed or refractory germ cell tumors. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group Genetic variation in AKT1, PTEN and the 8q24 locus, and the risk of testicular germ cell tumor. Differential Akt signalling in non-seminomatous testicular germ cell tumors. Cisplatin resistance in germ cell tumours: models and mechanisms Preclinical and clinical activity of sunitinib in patients with cisplatin-refractory or multiply relapsed germ cell tumors: a Canadian Urologic Oncology Group/German Testicular Cancer Study Group cooperative study Crosstalk between Meg3 and miR-1297 regulates growth of testicular germ cell tumor through PTEN/PI3K/AKT pathway Investigational targeted therapies for the treatment of testicular germ cell tumors Platinum-refractory germ cell tumors: an update on current treatment options and developments. Pazopanib in advanced germ cell tumors after chemotherapy failure: results of the open-label, single-arm, phase 2 Pazotest trial. Brentuximab Vedotin in CD30-Expressing Germ Cell Tumors After Chemotherapy Failure
author name string	wds:Q57837577-106C639C-A8FF-4D60-8E03-2E17231D8FD8 wds:Q57837577-1FC80772-4D19-48F7-8C57-D196F8FF06E8 wds:Q57837577-414334AF-CFDD-4CDB-BAE2-CF862A54BE41 wds:Q57837577-A1D9DED7-6C39-4204-839A-A5187AFC999A wds:Q57837577-A9488EBF-F08C-4326-8EDF-48238BCE666A wds:Q57837577-E401F1A0-FD5F-422E-B3C4-7F88FEF18F2E
author name string	Hans-Georg Kopp Annette Dieing Thomas Gauler Karin Oechsle Anja Lorch Marcus Hentrich
rdfs:label	Everolimus in patients with multiply relapsed or cisplatin refractory germ cell tumors: results of a phase II, single-arm, open-label multicenter trial (RADIT) of the German Testicular Cancer Study Group (en) Everolimus in patients with multiply relapsed or cisplatin refractory germ cell tumors: results of a phase II, single-arm, open-label multicenter trial (RADIT) of the German Testicular Cancer Study Group (nl)
skos:prefLabel	Everolimus in patients with multiply relapsed or cisplatin refractory germ cell tumors: results of a phase II, single-arm, open-label multicenter trial (RADIT) of the German Testicular Cancer Study Group (en) Everolimus in patients with multiply relapsed or cisplatin refractory germ cell tumors: results of a phase II, single-arm, open-label multicenter trial (RADIT) of the German Testicular Cancer Study Group (nl)
name	Everolimus in patients with multiply relapsed or cisplatin refractory germ cell tumors: results of a phase II, single-arm, open-label multicenter trial (RADIT) of the German Testicular Cancer Study Group (en) Everolimus in patients with multiply relapsed or cisplatin refractory germ cell tumors: results of a phase II, single-arm, open-label multicenter trial (RADIT) of the German Testicular Cancer Study Group (nl)
author	wds:Q57837577-1B06968F-495C-49B1-8AA0-64C8B2174D0A wds:Q57837577-682E6D83-F142-4600-9C1C-99477FBC539F wds:Q57837577-803A6586-6715-4D77-9B18-332E3096A394 wds:Q57837577-E0346F40-4A1C-4AF7-AA69-9DA743A65243
author	Martin Fenner Carsten Bokemeyer Christoph Oing Friedemann Honecker
title	wds:Q57837577-F9E46CD7-2403-49F6-BBAF-CEEBED3E2EC6
title	Everolimus in patients with multiply relapsed or cisplatin refractory germ cell tumors: results of a phase II, single-arm, open-label multicenter trial (RADIT) of the German Testicular Cancer Study Group (en)
page(s)	wds:Q57837577-FF9560E1-F8BB-4407-8F9E-66675972B07D
page(s)	717-723
instance of	wds:Q57837577-AA2FE825-DB3C-48FF-B9A8-B0C2D1A91BBD
instance of	scholarly article
main subject	wds:Q57837577-3AD61D02-5673-4114-AEDE-2230425BCAE5 wds:Q57837577-7B726764-1D59-42FE-89F0-389769404BE0 wds:Q57837577-D7CA70B8-A324-4A2E-A4E5-1943F6449F5D wds:Q57837577-F114B755-1ED2-48D2-BD9B-8C028DE368F4
main subject	cancer research multicenter clinical trial testicular cancer phase II clinical trial
PubMed ID	wds:Q57837577-E78F3D85-1F55-4871-B839-A96E9BCFDA05
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/30232558
PubMed ID	30232558
published in	wds:Q57837577-88194EE4-28A3-4888-A362-9B2F5BB83C6D
published in	Journal of Cancer Research and Clinical Oncology
issue	wds:Q57837577-1C75C34A-AE73-4114-A32C-2F92FF020014
volume	wds:Q57837577-81FB5F36-7D4B-41D8-8E07-D4FD60BBF13D
issue	3
volume	145
DOI	wds:Q57837577-7A15AB78-369E-43EE-A5C6-6800772E9DDC
DOI	http://dx.doi.org/10.1007/S00432-018-2752-Z
DOI	10.1007/S00432-018-2752-Z
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q57837577
is cites work of	Targeting mTOR and Metabolism in Cancer: Lessons and Innovations IGF signalling in germ cells and testicular germ cell tumours: roles and therapeutic approaches Contemporary management of ovarian germ cell tumors and remaining controversies Diverse Stakeholders of Tumor Metabolism: An Appraisal of the Emerging Approach of Multifaceted Metabolic Targeting by 3-Bromopyruvate
is cites work of	wds:Q91814537-2A5B59CC-E661-4862-8ECD-37E1F6ECD84C wds:Q92622946-D687BE48-7FA2-43F0-BE9C-5BACE72BA7E7 wds:Q96165945-C99CD667-A95D-4682-AEF1-C99C43B053C3

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 180 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software